Literature DB >> 20821210

Is a SUV cut-off necessary in the evaluation of the response of axillary lymph node metastases to neoadjuvant therapy?

Laura Gilardi, Giovanni Paganelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20821210     DOI： 10.1007/s00259-010-1578-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  4 in total

1.  Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy.

Authors:  Laura Gilardi; Concetta De Cicco; Marco Colleoni; Anna Cardillo; Emilia Montagna; Silvia Dellapasqua; Viviana Galimberti; Vincenzo Bagnardi; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-10       Impact factor: 9.236

2.  Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Authors:  Eleftherios P Mamounas; Ann Brown; Stewart Anderson; Roy Smith; Thomas Julian; Barbara Miller; Harry D Bear; Christopher B Caldwell; Alonzo P Walker; Wendy M Mikkelson; Jay S Stauffer; Andre Robidoux; Heather Theoret; Atilla Soran; Atilla Sovan; Bernard Fisher; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

3.  Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients.

Authors:  Marieke E Straver; Tjeerd S Aukema; Renato A Valdes Olmos; Emiel J T Rutgers; Kenneth G A Gilhuijs; Margaret E Schot; Wouter V Vogel; Marie-Jeanne T F D Vrancken Peeters
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-04       Impact factor: 9.236

Review 4.  Response to therapy in breast cancer.

Authors:  Norbert Avril; Stefanie Sassen; Rebecca Roylance
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.